HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript Summary
HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript Summary
Cash balance as of September 30, 2024, was $5.8 million.The following is a summary of the HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript:
以下是HeartBeam, Inc. (BEAT) 2024年第三季度業績會簡報：
Financial Performance:
財務表現:
HeartBeam reported a net loss for Q3 2024 of $5 million.
Adjusted net cash used in operating activities was $3.3 million.
Cash balance as of September 30, 2024, was $5.8 million.
HeartBeam報告2024年第三季度淨虧損爲500萬美元。
調整後的經營活動中使用的淨現金爲330萬美元。
截至2024年9月30日，現金餘額爲580萬美元。
Business Progress:
業務進展:
HeartBeam is progressing with its FDA submission for its groundbreaking 12-lead ECG technology.
The company has developed a vector-based 12-lead ECG that enhances cardiac care.
Management changes have been made to strengthen the team for commercialization.
HeartBeam anticipates foundational FDA clearance soon, which will lead to initial commercialization efforts.
HeartBeam正在推進其具有突破性的12導聯心電圖技術的FDA提交。
該公司開發了基於矢量的12導聯心電圖，可增強心臟護理。
管理層變動已經實施，以加強團隊的商業化能力。
HeartBeam預計很快將獲得基礎的FDA批准，這將引領初期的商業化努力。
Opportunities:
機會：
HeartBeam's technology has the potential to disrupt markets with a total worth of over $100 billion annually in the U.S.
The technology targets multiple large markets from symptom-driven diagnosis to monitoring and replacing traditional hospital ECGs.
HeartBeam的技術有潛力在美國每年價值超過1000億美元的市場中引發顛覆。
該技術針對多個大型市場，從症狀導向的診斷到監測，並取代傳統醫院的心電圖。
Risks:
風險：
The incremental advancements and FDA clearance of HeartBeam's technology involve significant regulatory challenges.
Dependency on FDA's approval timelines and responses for commercialization.
HeartBeam技術的漸進性改進和FDA批准涉及重大的監管挑戰。
依賴FDA的批准時間表和對商業化的回應。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
